Rhabdomyolysis in a patient receiving ranolazine and simvastatin

Hylton, Ann C.; Ezekiel, Tanya O.
November 2010
American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1829
Academic Journal
Case Study
Purpose. A case of rhabdomyolysis occurring shortly after the addition of ranolazine to a stable simvastatin regimen is reported. Summary. A 63-year-old Caucasian man with a history of hyperlipidemia and coronary artery disease arrived at an urgent care center with complaints of worsening bilateral lower-extremity weakness over three days. He was admitted to a hospital within 24 hours. His other underlying medical conditions included congestive heart failure, chronic kidney disease, degenerative joint disease, and a history of stroke. Oral medications at the time of admission included furosemide 40 mg daily, clopidogrel 75 mg daily, hydralazine 50 mg three times daily, metoprolol 50 mg twice daily, isosorbide mononitrate 120 mg daily, omeprazole 20 mg daily, nitroglycerin tablets as needed for chest pain, simvastatin 80 mg daily, and the recent addition of ranolazine 500 mg daily. Laboratory tests revealed that the patient's serum creatinine (SCr) concentration was 3.9 mg/dL and his creatine kinase (CK) concentration was 31,989 units/L. Ranolazine and simvastatin were discontinued, and metoprolol, hydralazine, isosorbide mononitrate, and furosemide were continued via nasogastric tube, along with amlodipine 10 mg daily and omeprazole 40 mg daily. The patient's serum CK concentration remained above 10,400 units/L for four days. By day 7 of hospitalization, the patient's serum CK concentration was 715 units/L, and it was almost undetectable by hospital day 18 (24 units/L). The patient's SCr concentration remained at his baseline value of 2.2 mg/dL. Conclusion. A 63-year-old man with a history of chronic renal impairment on a stable dosage of simvastatin developed rhabdomyolysis after the addition of ranolazine to his medication regimen.


Related Articles

  • Dyslipidaemia: integration between primary and secondary care. Skinner, Jane S. // Clinical Medicine;Jun2011, Vol. 11 Issue 3, p258 

    The article offers an overview of a session on dyslipidaemia that was covered of a conference organized by the British Geriatrics Society and the Royal College of Physicians (RCP) that was held on June 8, 2010. It explores the influence of lipid lowering drugs on the primary care of patients...

  • An Adolescent with Hyperimmunoglobulinemia D and Periodic Fever Syndrome Responding to Simvastatin Treatment. Karakoç-Aydiner, Elif; Özdemır, Cevdet; Keleş, Sevgi; Bariş, Safa; Bahçecıler, Nerin N.; Barlan, Işıl B. // Turkish Journal of Rheumatology;Jun2011, Vol. 26 Issue 2, p167 

    The hyperimmunoglobulinemia D and periodic fever syndrome is proposed to be caused by a defect in the activity of mevalonate kinase enzyme which is involved in cholesterol and non-sterol isoprenoid biosynthesis. This autosomal recessive inherited auto- inflammatory syndrome is characterized by...

  • Saxagliptin: a guide to its use in type 2 diabetes mellitus.  // Drugs & Therapy Perspectives;Aug2010, Vol. 26 Issue 8, p5 

    Oral saxagliptin, a potent, selective dipeptidyl peptidase-4 inhibitor, is a valuable option to improve glycaemic control in patients with type 2 diabetes mellitus. Saxagliptin as addon therapy to monotherapy with metformin, a sulphonylurea or a thiazolidinedione improves glycaemic control and...

  • Avoid high-dose simvastatin Increased risk of prostate cancer. Elliott, William T. // Primary Care Reports;Aug2011 Pharmacology Watch, p1 

    The article reports on the recommendation by the U.S. Food and Drug Administration (FDA) that physicians should avoid high-dose simvastatin due to the risk of myopathy and rhabdomyolysis associated with it. The FDA based its recommendation on the findings of the Study of the Effectiveness of...

  • A pilot in distress. Bennett, Sophie; Mitsides, Nicos; Dhaygude, Ajay; Woywodt, Alexander // NDT Plus;Feb2010, Vol. 3 Issue 1, p84 

    The article discusses the clinical case of a 77-year-old male pilot, diagnosed with chronic renal failure, who experienced distress and deteriorating renal function. Information on the medical history of the patient is given, including his medication and laboratory status. Clinical examinations...

  • Paracetamol overdose. Greener, Mark // Independent Nurse;12/5/2011, p17 

    The article presents a compilation of research on paracetamol overdose from various journals as of December 2011. A "Lancet" article reports that simvastatin is safe and effective based on the Heart Protection Study (HPS). Delayed presentation and repeated staggered paracetamol overdoses...

  • New protease inhibitor offers flexible dosing.  // Drug Topics;11/3/2003, Vol. 147 Issue 21, p10 

    Reports on the approval of the U.S. Food and Drug Administration for fosamprenavir, a protease inhibitor for the treatment of HIV infections in adults in combination with other antiretroviral agents. Provision of flexible dosing by the drug; Citation of side effects associated with the product.

  • Management of Lipid Disorders: Current and Future Treatment Options. Miller, Michael // Journal of Managed Care Medicine;2011, Vol. 14 Issue 2, p21 

    The management of lipid disorders continues to evolve. Although the majority of American adults have excessive levels of various atherogenic lipids, the data for treating these levels are best for those patients with higher levels of cardiovascular risk. Statins remain the mainstay of therapy,...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Dec2011 Pharmacology, p2 

    The article offers pharmacology news briefs as of December 2011. The FDA is reviewing the association of oral contraceptives, particularly those containing drospirenone, and thrombotic risk. The FDA has approved the first generic olanzapine (Zyprexa) for the treatment of schizophrenia and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics